Lack of influence of the apolipoprotein E genotype on the outcome of selegiline treatment in Alzheimer's disease

János Kálmán, Anna Juhász, Ágnes Rimanóczy, András Palotás, Miklós Palotás, Zoltán Szabó, Krisztina Boda, János Márki-Zay, Zoltán Janka

Research output: Contribution to journalArticle

3 Citations (Scopus)


The objective of our study was to investigate whether an interaction exists between apolipoprotein E (APOE) genotype and the response of patients with Alzheimer's disease (AD) to selegiline treatment, and whether APOE genotype independently affects the rate of AD progression. A 48-week multicenter double-blind trial was undertaken on 43 patients with mild to moderate AD. Primary efficacy measures were the AD Assessment Scale (ADAS), an 11-item cognitive subscale of ADAS (ADAS-Cog/11) and the Mini Mental State Examination. Secondary outcome measures were Clinical Global Impression of severity and CGI of change scales. The therapeutic response to selegiline was not affected by APOE genotype. Our results revealed that the APOE4 allele carrier AD probands did not respond better to selegiline treatment than the APOE2-3 patients, i.e. APOE status did not influence the therapeutic outcome of selegiline treatment.

Original languageEnglish
Pages (from-to)31-34
Number of pages4
JournalDementia and Geriatric Cognitive Disorders
Issue number1
Publication statusPublished - May 1 2003



  • Alzheimer's disease
  • Apolipoprotein E genotype
  • Clinical trial
  • Selegiline
  • Treatment response

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Cognitive Neuroscience
  • Psychiatry and Mental health

Cite this